2 July 2024
In this phase 2 NeoTrio trial, authors investigated whether targeted therapy could boost the proportion of patients achieving long-term recurrence-free survival with neoadjuvant immunotherapy in resectable stage III BRAFV600-mutant melanoma. The study concludes that pending longer follow-up, immunotherapy and targeted therapy should not be combined in the neoadjuvant setting for melanoma.
2 July 2024
According to results of this trial, after nearly 10 years of follow-up, adjuvant therapy with dabrafenib plus trametinib was associated with better relapse-free survival and distant metastasis–free survival than placebo among patients with resected stage III melanoma.
2 July 2024
Authors of this recent study compared melanoma incidence trends by age, sex, and anatomic site by analyzing long-term melanoma data (1982-2018) in three populations residing at high-, moderate- and low- ambient sun exposure. Results of the study suggest etiologic heterogeneity.
27 June 2024
Several studies have suggested that many melanomas metastasize long before the primary lesion is diagnosed. Therefore, waiting for dissemination of metastatic disease to become evident before making systemic therapy available to these patients may be less effective than giving them post-operative adjuvant therapy initially if the metastatic risk is high. The study concludes that further studies are required to better identify high-risk patients whose primary melanoma is likely to have already metastasized.
27 June 2024
Authors of this recent study reviewed published economic evaluations of primary prevention initiatives in the past decade, to support investment decisions for skin cancer prevention. The study concludes that from both population health and economic perspectives, allocating limited health care resources to primary prevention of skin cancer is highly favourable.
27 June 2024
According to this recent study, valine aminoacyl-tRNA synthetase (VARS) is a key player in the codon-biased translation reprogramming induced by resistance to targeted (MAPK) therapy in melanoma. The study concludes that VARS may represent an attractive therapeutic target for the treatment of therapy-resistant melanoma.
10 June 2024
According to this recent study, the incidence of invasive melanoma (IM) in New Zealand has plateaued in the last decade and was associated with an increase in melanoma in situ incidence over the same period. The study concludes that while this trend is encouraging, further research is required to investigate whether there is an actual decline in IM incidence.
10 June 2024
This systematic review aimed to analyse clinical outcomes for patients with invasive melanomas treated with Mohs rather than wide local excision (WLE). The study concludes that on the basis of currently available data, it is not possible to reliably assess whether outcomes differ if invasive melanomas with comparable features are treated with Mohs or WLE. Randomised trial evidence will be required for reliable conclusions to be reached.
7 June 2024
This review aims to summarise randomised controlled trials done to test photodynamic therapy effectiveness in BCC. The study concludes that photodynamic therapy is a safe and efficacious treatment option for superficial BCC and to a lesser extent nodular BCC.
5 June 2024
According to this recent study, rosacea is associated with some comorbidities and ethnicity may be a risk factor in melanoma development. The retrospective nature of this study and the sole use of ICD-10 code based filtering calls for future validation of the findings. Additionally, confounding factors such as skin type and previous UV exposure should be included in future studies.
